NCT00958152

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential-group, Multiple-dose, Drug-drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.

Conditions

• Hepatitis C

Interventions

Type	Name	Description
DRUG	VCH-222	Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
DRUG	VCH-222	Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
DRUG	VCH-222	Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
DRUG	telaprevir	Tablet, Oral, 1125 mg, q12h, Days 18-37

Timeline

• Start date: 2009-08-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2009-08-13
• Last updated: 2010-01-07

Locations

1 site across 1 country: New Zealand